Loading...
COVID-19 in solid organ transplant: A multi-center cohort study
Kates, Olivia S. Haydel, Brandy M. Florman, Sander S. Rana, Meenakshi M. Chaudhry, Zohra S. Ramesh, Mayur S. Safa, Kassem Kotton, Camille Nelson Blumberg, Emily A. Besharatian, Behdad D.
Kates, Olivia S.
Haydel, Brandy M.
Florman, Sander S.
Rana, Meenakshi M.
Chaudhry, Zohra S.
Ramesh, Mayur S.
Safa, Kassem
Kotton, Camille Nelson
Blumberg, Emily A.
Besharatian, Behdad D.
Citations
Altmetric:
Genre
Pre-print
Date
2020-08-07
Advisor
Committee member
Group
Department
Thoracic Medicine And Surgery
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1093/cid/ciaa1097
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic has led to significant reductions in transplantation, motivated in part by concerns of disproportionately more severe disease among solid organ transplant (SOT) recipients. However, clinical features, outcomes, and predictors of mortality in SOT recipients are not well described.
Methods: We performed a multicenter cohort study of SOT recipients with laboratory-confirmed COVID-19. Data were collected using standardized intake and 28-day follow-up electronic case report forms. Multivariable logistic regression was used to identify risk factors for the primary endpoint, 28-day mortality, among hospitalized patients.
Results: Four hundred eighty-two SOT recipients from >50 transplant centers were included: 318 (66%) kidney or kidney/pancreas, 73 (15.1%) liver, 57 (11.8%) heart, and 30 (6.2%) lung. Median age was 58 (interquartile range [IQR] 46–57), median time post-transplant was 5 years (IQR 2–10), 61% were male, and 92% had ≥1 underlying comorbidity. Among those hospitalized (376 [78%]), 117 (31%) required mechanical ventilation, and 77 (20.5%) died by 28 days after diagnosis. Specific underlying comorbidities (age >65 [adjusted odds ratio [aOR] 3.0, 95% confidence interval [CI] 1.7–5.5, P < .001], congestive heart failure [aOR 3.2, 95% CI 1.4–7.0, P = .004], chronic lung disease [aOR 2.5, 95% CI 1.2–5.2, P = .018], obesity [aOR 1.9, 95% CI 1.0–3.4, P = .039]) and presenting findings (lymphopenia [aOR 1.9, 95% CI 1.1–3.5, P = .033], abnormal chest imaging [aOR 2.9, 95% CI 1.1–7.5, P = .027]) were independently associated with mortality. Multiple measures of immunosuppression intensity were not associated with mortality.
Conclusions: Mortality among SOT recipients hospitalized for COVID-19 was 20.5%. Age and underlying comorbidities rather than immunosuppression intensity-related measures were major drivers of mortality.
Description
Citation
Olivia S Kates, Brandy M Haydel, Sander S Florman, et. al. Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study, Clinical Infectious Diseases, , ciaa1097, https://doi.org/10.1093/cid/ciaa1097
Citation to related work
Oxford University Press
Has part
Clinical Infectious Diseases
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu